Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors:  Exploring the Impact of Ring Size on Structure−Activity Relationships

Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 1996-09, Vol.39 (20), p.4125-4130
Hauptverfasser: Romines, Karen R, Morris, Jeanette K, Howe, W. Jeffrey, Tomich, Paul K, Horng, Miao-Miao, Chong, Kong-Teck, Hinshaw, Roger R, Anderson, David J, Strohbach, Joseph W, Turner, Steve R, Mizsak, Steve A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4130
container_issue 20
container_start_page 4125
container_title Journal of medicinal chemistry
container_volume 39
creator Romines, Karen R
Morris, Jeanette K
Howe, W. Jeffrey
Tomich, Paul K
Horng, Miao-Miao
Chong, Kong-Teck
Hinshaw, Roger R
Anderson, David J
Strohbach, Joseph W
Turner, Steve R
Mizsak, Steve A
description Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure−activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K i values in the 10−50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED50 values as low as 1 μM.
doi_str_mv 10.1021/jm960296c
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78382270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78382270</sourcerecordid><originalsourceid>FETCH-LOGICAL-a379t-e8848a2d829a165c0834214f6ae4f0c3892b3ff7715557f390fec8cd94fd495f3</originalsourceid><addsrcrecordid>eNptkc1u1DAURiMEKtPCggdA8gKQWAT8l9jurgyFGakSVaewtTyOzXiaxMF2qoYVS9iy4f36JGSU0bBhdaV7jq6uvi_LniH4BkGM3m4bUUIsSv0gm6ECw5xySB9mMwgxznGJyePsOMYthJAgTI6yI84JYkzMsj_zQdde1TdD3Q1Btb41Eai2Av_2ldsMVfAjnmAEi-UXcBl8MioasGw3bu2SD_H0_scvcH7X1T649itImxE2ndIJeAuudquV-26Ab8EqhV6nPpj7n7_PdHK3Lg3gytQqOd_Gjevik-yRVXU0T_fzJPv84fx6vsgvPn1czs8uckWYSLnhnHKFK46FQmWhIScUI2pLZaiFmnCB18RaxlBRFMwSAa3RXFeC2oqKwpKT7NV0twv-W29iko2L2tS1ao3vo2SccIwZHMXXk6iDjzEYK7vgGhUGiaDclSAPJYzu8_3Rft2Y6mDuUx_5iz1XUavajrlrFw8awQQyQUctnzQXk7k7YBVuZMkIK-T15UoSSN6_Wy2o3L34cvKVjnLr-9COyf3nvb895q6k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78382270</pqid></control><display><type>article</type><title>Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors:  Exploring the Impact of Ring Size on Structure−Activity Relationships</title><source>ACS Publications</source><source>MEDLINE</source><creator>Romines, Karen R ; Morris, Jeanette K ; Howe, W. Jeffrey ; Tomich, Paul K ; Horng, Miao-Miao ; Chong, Kong-Teck ; Hinshaw, Roger R ; Anderson, David J ; Strohbach, Joseph W ; Turner, Steve R ; Mizsak, Steve A</creator><creatorcontrib>Romines, Karen R ; Morris, Jeanette K ; Howe, W. Jeffrey ; Tomich, Paul K ; Horng, Miao-Miao ; Chong, Kong-Teck ; Hinshaw, Roger R ; Anderson, David J ; Strohbach, Joseph W ; Turner, Steve R ; Mizsak, Steve A</creatorcontrib><description>Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure−activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K i values in the 10−50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED50 values as low as 1 μM.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm960296c</identifier><identifier>PMID: 8831779</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>AIDS/HIV ; Anti-HIV Agents - chemical synthesis ; Anti-HIV Agents - metabolism ; Anti-HIV Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Aspartic Acid Endopeptidases - antagonists &amp; inhibitors ; Aspartic Acid Endopeptidases - chemistry ; Aspartic Acid Endopeptidases - metabolism ; Binding Sites ; Biological and medical sciences ; Crystallography, X-Ray ; Cyclization ; HIV Protease ; HIV Protease Inhibitors - chemical synthesis ; HIV Protease Inhibitors - metabolism ; HIV Protease Inhibitors - pharmacology ; Medical sciences ; Models, Molecular ; Molecular Structure ; Pharmacology. Drug treatments ; Protein Conformation ; Pyrones - chemistry ; Pyrones - metabolism ; Pyrones - pharmacology ; Structure-Activity Relationship ; Sulfonamides - chemistry</subject><ispartof>Journal of medicinal chemistry, 1996-09, Vol.39 (20), p.4125-4130</ispartof><rights>Copyright © 1996 American Chemical Society</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a379t-e8848a2d829a165c0834214f6ae4f0c3892b3ff7715557f390fec8cd94fd495f3</citedby><cites>FETCH-LOGICAL-a379t-e8848a2d829a165c0834214f6ae4f0c3892b3ff7715557f390fec8cd94fd495f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm960296c$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm960296c$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3230794$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8831779$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romines, Karen R</creatorcontrib><creatorcontrib>Morris, Jeanette K</creatorcontrib><creatorcontrib>Howe, W. Jeffrey</creatorcontrib><creatorcontrib>Tomich, Paul K</creatorcontrib><creatorcontrib>Horng, Miao-Miao</creatorcontrib><creatorcontrib>Chong, Kong-Teck</creatorcontrib><creatorcontrib>Hinshaw, Roger R</creatorcontrib><creatorcontrib>Anderson, David J</creatorcontrib><creatorcontrib>Strohbach, Joseph W</creatorcontrib><creatorcontrib>Turner, Steve R</creatorcontrib><creatorcontrib>Mizsak, Steve A</creatorcontrib><title>Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors:  Exploring the Impact of Ring Size on Structure−Activity Relationships</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure−activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K i values in the 10−50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED50 values as low as 1 μM.</description><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - chemical synthesis</subject><subject>Anti-HIV Agents - metabolism</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Aspartic Acid Endopeptidases - antagonists &amp; inhibitors</subject><subject>Aspartic Acid Endopeptidases - chemistry</subject><subject>Aspartic Acid Endopeptidases - metabolism</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Crystallography, X-Ray</subject><subject>Cyclization</subject><subject>HIV Protease</subject><subject>HIV Protease Inhibitors - chemical synthesis</subject><subject>HIV Protease Inhibitors - metabolism</subject><subject>HIV Protease Inhibitors - pharmacology</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Molecular Structure</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Conformation</subject><subject>Pyrones - chemistry</subject><subject>Pyrones - metabolism</subject><subject>Pyrones - pharmacology</subject><subject>Structure-Activity Relationship</subject><subject>Sulfonamides - chemistry</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc1u1DAURiMEKtPCggdA8gKQWAT8l9jurgyFGakSVaewtTyOzXiaxMF2qoYVS9iy4f36JGSU0bBhdaV7jq6uvi_LniH4BkGM3m4bUUIsSv0gm6ECw5xySB9mMwgxznGJyePsOMYthJAgTI6yI84JYkzMsj_zQdde1TdD3Q1Btb41Eai2Av_2ldsMVfAjnmAEi-UXcBl8MioasGw3bu2SD_H0_scvcH7X1T649itImxE2ndIJeAuudquV-26Ab8EqhV6nPpj7n7_PdHK3Lg3gytQqOd_Gjevik-yRVXU0T_fzJPv84fx6vsgvPn1czs8uckWYSLnhnHKFK46FQmWhIScUI2pLZaiFmnCB18RaxlBRFMwSAa3RXFeC2oqKwpKT7NV0twv-W29iko2L2tS1ao3vo2SccIwZHMXXk6iDjzEYK7vgGhUGiaDclSAPJYzu8_3Rft2Y6mDuUx_5iz1XUavajrlrFw8awQQyQUctnzQXk7k7YBVuZMkIK-T15UoSSN6_Wy2o3L34cvKVjnLr-9COyf3nvb895q6k</recordid><startdate>19960927</startdate><enddate>19960927</enddate><creator>Romines, Karen R</creator><creator>Morris, Jeanette K</creator><creator>Howe, W. Jeffrey</creator><creator>Tomich, Paul K</creator><creator>Horng, Miao-Miao</creator><creator>Chong, Kong-Teck</creator><creator>Hinshaw, Roger R</creator><creator>Anderson, David J</creator><creator>Strohbach, Joseph W</creator><creator>Turner, Steve R</creator><creator>Mizsak, Steve A</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960927</creationdate><title>Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors:  Exploring the Impact of Ring Size on Structure−Activity Relationships</title><author>Romines, Karen R ; Morris, Jeanette K ; Howe, W. Jeffrey ; Tomich, Paul K ; Horng, Miao-Miao ; Chong, Kong-Teck ; Hinshaw, Roger R ; Anderson, David J ; Strohbach, Joseph W ; Turner, Steve R ; Mizsak, Steve A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a379t-e8848a2d829a165c0834214f6ae4f0c3892b3ff7715557f390fec8cd94fd495f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - chemical synthesis</topic><topic>Anti-HIV Agents - metabolism</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Aspartic Acid Endopeptidases - antagonists &amp; inhibitors</topic><topic>Aspartic Acid Endopeptidases - chemistry</topic><topic>Aspartic Acid Endopeptidases - metabolism</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Crystallography, X-Ray</topic><topic>Cyclization</topic><topic>HIV Protease</topic><topic>HIV Protease Inhibitors - chemical synthesis</topic><topic>HIV Protease Inhibitors - metabolism</topic><topic>HIV Protease Inhibitors - pharmacology</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Molecular Structure</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Conformation</topic><topic>Pyrones - chemistry</topic><topic>Pyrones - metabolism</topic><topic>Pyrones - pharmacology</topic><topic>Structure-Activity Relationship</topic><topic>Sulfonamides - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romines, Karen R</creatorcontrib><creatorcontrib>Morris, Jeanette K</creatorcontrib><creatorcontrib>Howe, W. Jeffrey</creatorcontrib><creatorcontrib>Tomich, Paul K</creatorcontrib><creatorcontrib>Horng, Miao-Miao</creatorcontrib><creatorcontrib>Chong, Kong-Teck</creatorcontrib><creatorcontrib>Hinshaw, Roger R</creatorcontrib><creatorcontrib>Anderson, David J</creatorcontrib><creatorcontrib>Strohbach, Joseph W</creatorcontrib><creatorcontrib>Turner, Steve R</creatorcontrib><creatorcontrib>Mizsak, Steve A</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romines, Karen R</au><au>Morris, Jeanette K</au><au>Howe, W. Jeffrey</au><au>Tomich, Paul K</au><au>Horng, Miao-Miao</au><au>Chong, Kong-Teck</au><au>Hinshaw, Roger R</au><au>Anderson, David J</au><au>Strohbach, Joseph W</au><au>Turner, Steve R</au><au>Mizsak, Steve A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors:  Exploring the Impact of Ring Size on Structure−Activity Relationships</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1996-09-27</date><risdate>1996</risdate><volume>39</volume><issue>20</issue><spage>4125</spage><epage>4130</epage><pages>4125-4130</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure−activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K i values in the 10−50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED50 values as low as 1 μM.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>8831779</pmid><doi>10.1021/jm960296c</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1996-09, Vol.39 (20), p.4125-4130
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_78382270
source ACS Publications; MEDLINE
subjects AIDS/HIV
Anti-HIV Agents - chemical synthesis
Anti-HIV Agents - metabolism
Anti-HIV Agents - pharmacology
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Aspartic Acid Endopeptidases - antagonists & inhibitors
Aspartic Acid Endopeptidases - chemistry
Aspartic Acid Endopeptidases - metabolism
Binding Sites
Biological and medical sciences
Crystallography, X-Ray
Cyclization
HIV Protease
HIV Protease Inhibitors - chemical synthesis
HIV Protease Inhibitors - metabolism
HIV Protease Inhibitors - pharmacology
Medical sciences
Models, Molecular
Molecular Structure
Pharmacology. Drug treatments
Protein Conformation
Pyrones - chemistry
Pyrones - metabolism
Pyrones - pharmacology
Structure-Activity Relationship
Sulfonamides - chemistry
title Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors:  Exploring the Impact of Ring Size on Structure−Activity Relationships
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A36%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cycloalkylpyranones%20and%20Cycloalkyldihydropyrones%20as%20HIV%20Protease%20Inhibitors:%E2%80%89%20Exploring%20the%20Impact%20of%20Ring%20Size%20on%20Structure%E2%88%92Activity%20Relationships&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Romines,%20Karen%20R&rft.date=1996-09-27&rft.volume=39&rft.issue=20&rft.spage=4125&rft.epage=4130&rft.pages=4125-4130&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm960296c&rft_dat=%3Cproquest_cross%3E78382270%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78382270&rft_id=info:pmid/8831779&rfr_iscdi=true